ClinicalTrials.Veeva

Menu

Idiopathic Generalized Epilepsy Syndromes

S

Shen Chun-Hong

Status

Enrolling

Conditions

Epilepsy
Epilepsy, Idiopathic Generalized

Study type

Observational

Funder types

Other

Identifiers

NCT06388174
S2022-0336

Details and patient eligibility

About

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.

According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Full description

the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.

Enrollment

200 estimated patients

Sex

All

Ages

4 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
  • Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
  • Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
  • Sign the informed consent forms.

Exclusion criteria

  • Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
  • Lost to follow-up

Trial contacts and locations

1

Loading...

Central trial contact

Chunhong Shen

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems